1.American Diabetes Association: Diabetes 2001 Vital Statistics. American Diabetes Association, Inc., 2001.

2.White paper: National Diabetes Fact Sheet 2002. American Diabetes Association. Available at: http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet.jsp. Accessed March 5, 2006.

3.Rolla A: The pathophysiological basis for intensive insulin replacement. Int J Obes Relat Metab Disord 2004;28:S3 S7.

4.UK Prospective Diabetes Study Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854 865.

5.Kahn SE: The relative contributions of insulin resistance and beta cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3 19.

6.DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281 303.

7.Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821-827.

8.Garber A, Marre M, Blonde L, Allavoine T, Howlett H, Lehert P, Cornes M: Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single tablet metformin-glibenclamide therapy (Glucovance®) in type 2 diabetes. Diabetes Obes Metab 2003;5:171 179.

9.Purnell JQ, Weyer C: Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33 47.

10.Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46:1954 1962.

11.Lewis JT, Dayanandan B, Habener JF, Kieffer TJ: Glucose dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 2000;141:3710 3716.

12.Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM: Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest. 1996;98:2440-2445.

13.Kolligs F, Fehmann HC, Goke R, Goke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-19.

14.Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93.

15.Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Yutaka, S: Glucose intolerance caused by a defect in the entero insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci 1999;96:14843-14847.

16.Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL,Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med.1996;2:1254-1258.

17.Persson K, Gingerich RL, Nayak S, Wada K, Wada E, Ahren B: Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am J Physiol Endocrinol Metab.2000;279:E956-E962.

18.Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK,Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2diabetic patients. J Clin Endocrinol Metab.2001;86:3717-3723.

19.Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Amer J Physiol Endocrinol Metab.2004;287:E199 E206.

20.Brown JC, Pederson RA: A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin.Scand J Gastroenterol.1970;5:537-541.

21.Brown JC: A gastric inhibitory polypeptide-1: The amino acid composition and the tryptic peptides. Can J Biochem.1971;49:255-261.

22.Dupre J, Ross SA, Watson D, Brown JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826-828.

23.Mortensen K, Petersen LL, Orskov C: Colocalization of GLP 1 and GIP in human and porcine intestine. Ann NY Acad Sci 2000;921:469 472.

24.Buffa R, Polak JM, Pearse AGE, Solcia E, Grimelius L, Capella C: Identification of the intestinal cell storing gastric inhibitory peptide. Histochemistry 1975;43:249 255.

25.Vilsbøll T, Holst JJ: Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357 366.

26.Vilsbøll T, Krarup T, Madsbad S, Holst JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002;45:1111 1119.

27.Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA: Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.Diabetologia 2003;46:798-801.

28.Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B,Nauck MA: Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.Am J Physiol Endocrinol Metab.2004;286:E621-E625.

29.Rothenberg ME, Eilertson CD, Klein K, Zhou Y, Lindberg I, McDonald JK,Mackin RB, Noe BD: Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. J Biol Chem.1995;270:10136-10146.

30.Rouille Y, Kantengwa S, Irminger JC, Halban PA: Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem.1997;272:32810-32816.

31.Ugleholdt R, Zhu X, Deacon CF, Orskov C, Steiner DF, Holst JJ: Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.Endocrinology.2004;145:1349-1355.

32.Orskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable.Diabetes.1993;42:658-661.

33.Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-likepeptide I in humans. Diabetes.1994;43:535-539.

34.Kieffer TJ, Habener JF: The glucagon like peptides. Endocr Rev 1999;20:876 913.

35.Deacon CF, Nauck MA, Toft Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon like peptide I are rapidly degraded from the NH2 terminus in type II diabetic patients and in healthy subjects. Diabetes.1995;44:1126 1131.

36.Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV: Glucagon like peptides GLP 1 and GLP 2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986;119:1467 1475.

37.Holst JJ: Glucagon like Peptide 1(GLP 1): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab.1999;10:229 235.

38.Drucker DJ: Glucagon like peptides. Diabetes 1998;47:159 169.

39.Zander M, Madsbad S, Madsen, JL, Holst JJ: Effect of 6 week course of glucagon like peptide 1 on glycaemic control, insulin sensitivitiy, and β cell function in type 2 diabetes: a parallel group study. Lancet 2002;359:824 830.

40.Parkes DG, Pittner R, Jodka C, Smith P, Young A: Insulinotropic actions of exendin 4 and glucagon like peptide 1 in vivo and in vitro. Metabolism 2001;50:583 589.

41.Rayner CK, Samsom M, Jones KL, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001;24:371 381.

42.Flint A, Raben A, Astrup A, Holst JJ: Glucagon like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515 520.

43.Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM: Energy intake and appetite are suppressed by glucagon like peptide 1 (GLP 1) in obese men. Int J Obes Relat Metab Disord 1999;23:304 311.

44.Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C: Glucagon like peptide 1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541 R1544.

45.Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-5158.

46.Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B: Glucagon like peptide 1 and exendin 4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562 1570.

47.Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B: Persistent improvement of type 2 diabetes in the Goto Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon like peptide 1 or exendin 4. Diabetes 2002;51:1443 1452.

48.Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon like peptide 1 and exendin 4 convert pancreatic AR42J cells into glucagon and insulin producing cells. Diabetes 1999;48:2358 2366.

49.Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon like peptide 1 induces cell proliferation and pancreatic duodenum homeobox 1 expression and increases endocrine cell mass in the pancreas of old, glucose intolerant rats. Endocrinology 2000;141:4600 4605.

50.Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 1994;37:1163-1166.

51.Morales M, Lopez-Delgado MI, Alcantara A, Luque MA, Clemente F, Marquez L,Puente J, Vinambres C, Malaisse WJ, Villanueva-Penacarrillo ML, Valverde I: Preserved GLP-I effects on glycogen synthase a activity and glucose metabolismin isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997;46:1264-1269.

52.Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I: Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue.J Clin Endocrinol Metab. 1993;77:1654-1657.

53.Furnsinn C, Ebner K, Waldhausl W: Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 1995;38:864-867.

54.Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-2978.

55.Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-224.

56.Barragan JM, Rodriguez RE, Blazquez E: Changes in arterial blood pressure and heart rate induced by glucagon-likepeptide-1-(7-36) amide in rats. Am J Physiol 1994;266:E459-E466.

57.Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q,Drucker DJ, Husain M: Cardiac function in mice lacking the glucagon-like peptide-1 receptor.Endocrinology 2003;144:2242-2252.

58.Vilsbøll T, Agerso H, Krarup T, Holst JJ: Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.J Clin Endocrinol Metab. 2003;88:220-224.

59.Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose dependent insulinotropic polypeptide and truncated glucagon like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585 3596.

60.Drucker DJ: Minireview: the glucagon like peptides. Endocrinology 2001;142:521 527.

61.Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med.1992;326:1316-1322.

62.Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S: The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996;19:1200-1206.

63.Larsen J, Hylleberg B, Ng K, Damsbo P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001;24:1416-1421.

64.Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D: Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003;26:2835-2841.

65.Zander M, Christiansen A, Madsbad S, Holst JJ: Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 2004;27:1910-1914.

66.Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem. 1992;267:7402 7405.

67.Young AA: Glucagon like peptide 1, exendin and insulin sensitivity. Hansen B, Shafrir E, Eds. In Insulin Resistance and Insulin Resistance Syndrome. New York, NY. Harwood Academic Press, 2002; p235 262.

68.Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin 4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282 1290.

69.Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin 4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082 3089.

70.Xu G, Stoffers DA, Habener JF, Bonner Weir S: Exendin 4 stimulates both β cell replication and neogenesis, resulting in increased beta cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270 2276.

71.Bhavsar SP, Watkins JJ, Young AA: Comparison of central and peripheral effects of exendin 4 and GLP 1 on food intake in rats (Abstract). In Program and Abstracts: 80th Annual Meeting of the Endocrine Society 1998;A433.

72.Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM: Exendin 4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000;141:1936 1941.

73.Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose lowering and insulin sensitizing actions of exendin 4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026 1034.

74.Edwards CMB, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin 4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155 E161.

75.Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Amer J Health Sys Pharm 2005;62:173 181.

76.Amylin Pharmaceuticals, Inc. Byetta® (exenatide injection) package insert. San Diego CA:2006.

77.Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA: Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab.2005;90:5991-5997

78.Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O: Effect of intravenous infusion of exenatide (synthetic exendin 4) on glucose dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397 2403.

79.Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; for the Exenatide-113 Clinical Study Group: Effects of exenatide (exendin 4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care 2004;27:2628 2635.

80.DeFronzo R, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin 4) on glycemic control and weight over 30 weeks in metformin treated patients with type 2 diabetes. Diabetes Care 2005;28:1092 1100.

81.Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin 4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083 1091.

82.Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD: Effectiveness of progressive dose escalation of exenatide (exendin 4) in reducing dose limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004;20:411 417.

83.Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569

84.Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-2377.

85.Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D: Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005 Jun;7(3):467-77.

86.Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long acting GLP 1 derivative, in healthy men. Diabetologia 2002;45:195 202.

87.Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week's treatment with the long acting glucagon like peptide 1 derivative liraglutide (NN2211) markedly improves 24 h glycemia and α and β cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187 1194.

88.Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB: The GLP 1 derivative NN2211 restores β cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786 1791.

89.Harder H, Nielsen L, Thi TDT, Astrup A: The effect of liraglutide, a long acting glucagon like peptide 1 derivative, on glycemic control, body composition, and 24 h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915 1921.

90.Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a long acting GLP 1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424 429.

91.Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR: on behalf of the NN2211 1310 International Study Group: Improved glycemic control with no weight increase in patients with type 2 diabetes after once daily treatment with the long acting glucagon like peptide 1 analog liraglutide (NN2211): a 12 week, double blind, randomized, controlled trial. Diabetes Care 2004;27:1335 1342.

92.Nauck MA, Hompesch M, Filipczak R, Le TDT, Nielsen L, Zdravkovic M, Gumprecht J: Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add on to metformin in type 2 diabetes (Abstract). Diabetes 2004;53:A356-OR.

93.Feinglos MN, Saad MF, Pi Sunyer FX, An B, Santiago O; on behalf of the Liraglutide dose Response Study Group: Effects of liraglutide (NN2211), a long acting GLP 1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 2005;22:1016 1023.

94.Mest HJ, Mentlein R: Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005;48:616-620

95.Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase 4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 Diabetes. J Clin Endocrinol Metab 2004;89:2078 2084.

96.Herman GA, Zhao P-L, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Hilliard D, Tanen M, De Lepeleire I, Cilissen C, Stevens C, Tanaka W, Gottesdiener KM, Wagner JA: The DP IV inhibitor MK 0431 enhances active GLP 1 and reduces glucose following an OGTT in type 2 diabetics (Abstract). Diabetes 2004;53:A82.

97.Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double blind, placebo controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675 688.

98.Pratley R, Galbreath E: Twelve week monotherapy with the DPP 4 inhibitor, LAF237 improves glycemic control in patients with type 2 diabetes (T2DM) (Abstract). Diabetes 2004;53:A83.

99.Ahren B, Gomis R, Mills D, Schweizer A: The DPP 4 inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin (Abstract). Diabetes 2004;53:A83.

100.Ristic S, Byiers S, Foley J, Holmes D: Improved glycaemic control with dipeptidyl peptidase 4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692 698.

101.Ahren B, Pacini G, Foley JE, Schweizer A: Improved meal related β-cell function and insulin sensitivity by the dipeptidyl peptidase IV inhibitor vildagliptin in metformin treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936 1940.